[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-341979-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-341979-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","long-range-alternative-splicing-contributes-to-neoantigen-specificity-in-glioblastoma-case-study","Long-range alternative splicing contributes to neoantigen specificity in glioblastoma - Case Study","","Recent advances in neoantigen research have accelerated immunotherapy development for cancers including glioblastoma (GBM). Neoantigens from genomic mutations and dysregulated alternative splicing have been studied, yet prior work largely emphasized annotated alternatively spliced transcripts, leaving non-annotated forms unclear. Here, tumor versus healthy comparisons identified tumor-specific long-range alternatively spliced transcripts enriched in GBM. In silico translation prediction and MS-based immunopeptidome profiling highlighted MHC class I associated peptides as candidate GBM immunotherapy targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/long-range-alternative-splicing-contributes-to-neoantigen-specificity-in-glioblastoma-case-study/341979/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/long-range-alternative-splicing-contributes-to-neoantigen-specificity-in-glioblastoma-case-study/341979.png","ImageObject",300,407,{"name":42,"@type":43},"Sage","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What gap does the study address in neoantigen research for GBM?","Question",{"text":63,"@type":64},"The study highlights that previous work mainly analyzed annotated alternatively spliced transcripts, while non-annotated alternatively spliced transcripts remained largely unexplored in GBM immunotherapies.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were long-range alternatively spliced transcripts (LRs) identified and compared?",{"text":68,"@type":64},"Tumor and healthy tissues were compared to find tumor-specific LRs with higher abundance in GBM relative to normal tissues and other tumor types.",{"name":70,"@type":61,"acceptedAnswer":71},"What experimental/analytical methods were used to assess immunotherapy relevance?",{"text":72,"@type":64},"The study used in silico translation prediction and MS-based immunopeptidome analysis to identify MHC class I associated peptides as potential immunotherapy targets in GBM.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},341979,1790509013,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":112,"preview_page_count":33,"preview_urls":145},687197207057,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Briefings in Bioinformatics, 2024, 25(6), bbae503  \n[https://doi.org/10.1093/bib/bbae503](https://doi.org/10.1093/bib/bbae503)  \nCase Study  \nLong-range alternative splicing contributes toneoantigen specificity in glioblastoma  \nMingjunJi1 , Qing Yu1 , Xin-Zhuang Yang2 , Xianhong Yu3 , Jiaxin Wang1 , Chunfu Xiao1 , Ni A. An4 , Chuanhui Han5 , Chuan-Yun Li 1 , 6 , 7 , *, Wanqiu Ding 1 , 8 , *  \n1 State Key Laboratory of Protein and Plant Gene Research, Laboratory of Bioinformatics and Genomic Medicine, Institute of Molecular Medicine, College of Future Technology, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China  \n2 Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine and Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 9 Dongdan Santiao, Dongcheng District, Beijing 100730, China  \n3Academic Department, Shanghai MobiDrop Co. , Ltd., Room 308, Building 1, No. 351 Guoshoujing Road, Shanghai Free Trade Pilot Zone, Shanghai 200000, China  \n4 Institute of Genetics and Developmental Biology, Chinese Academy of Sciences, No. 1 West Beichen Road, Chaoyang District, Beijing 100101, China  \n5 School of Basic Medical Sciences, Peking University, No. 38 Xueyuan Road, Haidian District, Beijing 100191, China  \n6 Chinese Institute for Brain Research, No. 26 Science Park Road, Changping District, Beijing 102206, China  \n7 Southwest United Graduate School, 121 Dajie, Wuhua District, Kunming 650092, China  \n8 Bioinformatics Core Facility, Institute of Molecular Medicine, College of Future Technology, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China  \n*Corresponding authors. Chuan-Yun Li, College of Future Technology, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China.  \nE-mail: [chuanyunli@pku.edu.cn](chuanyunli@pku.edu.cn); Wanqiu Ding, College of Future Technology, Peking University, No. 5 Yiheyuan Road, Haidian District, Beijing 100871, China.  \nE-mail: [dingwq@pku.edu.cn](dingwq@pku.edu.cn)  \nAbstract  \nRecent advances in neoantigen research have accelerated the development of immunotherapies for cancers, such as glioblastoma (GBM) . Neoantigens resulting from genomic mutations and dysregulated alternative splicing have been studied in GBM. However, these studies have primarily focused on annotated alternatively-spliced transcripts, leaving non-annotated transcripts largely unexplored. Circular ribonucleic acids (circRNAs), abnormally regulated in tumors, are correlated with the presence of non-annotated linear transcripts with exon skipping events. But the extent to which these linear transcripts truly exist and their functions in cancer immunotherapies remain unknown. Here, we found the ubiquitous co-occurrence of circRNA biogenesis and alternative splicing across various tumor types, resulting in large amounts of long-range alternatively-spliced transcripts (LRs) . By comparing tumor and healthy tissues, we identified tumor-specific LRs more abundant in GBM than in normal tissues and other tumor types. This maybe attributable to the upregulation of the protein quaking in GBM, which is reported to promote circRNA biogenesis. In total, we identified 1057 specific and recurrent LRsin GBM. Through in silico translation prediction and MS-based immunopeptidome analysis,16 major histocompatibility complex class I-associated peptides were identified as potential immunotherapy targets in GBM. This study revealed long-range alternatively-spliced transcripts specifically upregulated in GBM may serve as recurrent, immunogenic tumorspecific antigens.  \nKeywords: circRNA; alternative splicing; neoantigen  \nIntroduction  \nImmune checkpoint inhibitors (ICIs) improve survival in many cancer types, such as melanoma and hepatocellular carcinoma, but are not equally effective in all types of solid tumors [1] . In particular, cancers with a high tumo","cbCaisNOJsm5VSQv","https://ap.wps.com/l/cbCaisNOJsm5VSQv","pdf",2037720,12,"English","# Abstract\n# Introduction\n# Received and revised dates\n# Publication and licensing","[{\"question\":\"What gap does the study address in neoantigen research for GBM?\",\"answer\":\"The study highlights that previous work mainly analyzed annotated alternatively spliced transcripts, while non-annotated alternatively spliced transcripts remained largely unexplored in GBM immunotherapies.\"},{\"question\":\"How were long-range alternatively spliced transcripts (LRs) identified and compared?\",\"answer\":\"Tumor and healthy tissues were compared to find tumor-specific LRs with higher abundance in GBM relative to normal tissues and other tumor types.\"},{\"question\":\"What experimental/analytical methods were used to assess immunotherapy relevance?\",\"answer\":\"The study used in silico translation prediction and MS-based immunopeptidome analysis to identify MHC class I associated peptides as potential immunotherapy targets in GBM.\"}]","Long-range alternative splicing contributes to neoantigen specificity in glioblastoma - Case Study | PDF",1790044606,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b48a34a5b1b61498ce93b47c325e156a.webp",983,1291,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a48cd61708b59316044834fffe6163fd.webp",982,1290,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a6335705c16e21f388ab291008f75417.webp",981,1289,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/735e6373e486ca2793805b02c135a6c5.webp",980,1287]